The involvement of platelets and the c-mpl receptor in the regulation of thrombopoietin (TPO) plasma concentrations and tissue mRNA levels was investigated in both normal mice and mice defective in c-mpl (c-mpl-'-). Although cmpl-'-mice have fewer platelets and higher plasma TPO activity than normal mice, there was no increase in TPO mRNA levels as measured by an S1 nuclease protection assay. After the intravenous injection of '"I-TPO, specific uptake of radioactivity by the spleen and blood cells was present in the normal mice, but absent in the c-mpl-'-mice. Platelet-rich plasma (PRP) from normal mice was able to bind and internalize '251-TP0, whereas PRP from c-mpl-/-mice lacked this ability. Analysis of '251-TP0 binding to nor-LATELETS ARE small anucleated cells that play an important role in wound healing and blood clotting. Normal hemostasis requires the maintenance of an adequate number of functional platelets in the blood. Production of circulating blood cells by bone marrow cells is mediated by humoral hematopoietic growth factors. The primary regulator of platelet production has recently been identified as the ligand for the c-mpl protooncogene'.2 and has been termed thrombopoietin (TPO)3-s or megakaryocyte growth and development factor (MGDF). In vitro, TPO supports both megakaryocyte colony formation6-@ and the formation of fully mature megakaryocytes and functional platelets in liquid culture^.^"^ Injection of recombinant TPO into mice and nonhuman primates increases platelet counts, spleen and bone marrow megakaryocytes, colony-forming units-megakaryocyte (CFU-MK),3-63" and burst-forming unit erythrocyte.I2*" Mice defective in the c-mpl or the TPO gene show a greater than 80% reduction in their megakaryocyte and platelet numbers, without affecting the other hematopoietic lineages.I4*I5 These results indicate that TPO is the primary physiologic regulator of both proliferation and differentiation of hematopoietic progenitor cells into mature megakaryocytes.
The involvement of platelets and the c-mpl receptor in the regulation of thrombopoietin (TPO) plasma concentrations and tissue mRNA levels was investigated in both normal mice and mice defective in c-mpl (c-mpl-'-). Although cmpl-'-mice have fewer platelets and higher plasma TPO activity than normal mice, there was no increase in TPO mRNA levels as measured by an S1 nuclease protection assay. After the intravenous injection of '"I-TPO, specific uptake of radioactivity by the spleen and blood cells was present in the normal mice, but absent in the c-mpl-'-mice. Platelet-rich plasma (PRP) from normal mice was able to bind and internalize '251-TP0, whereas PRP from c-mpl-/-mice lacked this ability. Analysis of '251-TP0 binding to nor-LATELETS ARE small anucleated cells that play an important role in wound healing and blood clotting. Normal hemostasis requires the maintenance of an adequate number of functional platelets in the blood. Production of circulating blood cells by bone marrow cells is mediated by humoral hematopoietic growth factors. The primary regulator of platelet production has recently been identified as the ligand for the c-mpl protooncogene'.2 and has been termed thrombopoietin (TPO)3-s or megakaryocyte growth and development factor (MGDF). In vitro, TPO supports both megakaryocyte colony formation6-@ and the formation of fully mature megakaryocytes and functional platelets in liquid culture^.^"^ Injection of recombinant TPO into mice and nonhuman primates increases platelet counts, spleen and bone marrow megakaryocytes, colony-forming units-megakaryocyte (CFU-MK),3-63" and burst-forming unit erythrocyte.I2*" Mice defective in the c-mpl or the TPO gene show a greater than 80% reduction in their megakaryocyte and platelet numbers, without affecting the other hematopoietic lineages.I4*I5 These results indicate that TPO is the primary physiologic regulator of both proliferation and differentiation of hematopoietic progenitor cells into mature megakaryocytes.
Circulating levels of TPO present in the serum of thrombocytopenic animals are elevated,4.'.I6"@ suggesting that TPO is the physiologic regulator of platelet production during a platelet emergency situation. However, the mechanism by mal PRP indicated that binding was specific and saturable, with an approximate affinity of 560 pmol/L and 220 receptors per platelet. PRP from normal mice was also able to degrade '%TPO into lower molecular weight fragments. After the intravenous injections, c-mpl-/-mice cleared a dose of '251-TP0 at a much slower rate than did normal mice. Injection of washed platelets from normal mice into c-mpl-'-mice resulted in a dramatic, but transient, decrease in plasma TPO levels. These data provide evidence that platelets regulate plasma TPO levels via binding to the cmpl receptor on circulating platelets. 0 7996 by The American Society of Hematology.
which the production of TPO is upregulated when there is a need for more platelets remains to be elucidated. The regulation of erythropoietin (EPO) production in the erythroid system is more clearly understood. A sensing mechanism in the kidney detects any decrease in oxygen pressure and then upregulates the transcription of the EPO gene accordingly." The subsequent increase in plasma EPO levels stimulates an increase in erythrocyte production and thereby increases the oxygen pressure in the blood. Such a mechanism could possibly be involved in the regulation of TPO production in response to a thrombocytopenic situation. However, it would require an as yet unidentified platelet sensing mechanism. An alternative model, whereby TPO levels are directly regulated by the platelets, has been proposed to account for the elevated levels of circulating TPO in the serum of thrombocytopenic animals.'K.20-22
Mice genetically altered to be defective in c-mpl (c-mpl"'") have low platelet and megakaryocyte numbers and elevated TPO levels2' and have provided the first animal model of chronic thrombocytopenia. We used these mice to analyze the mechanisms leading to the increased concentrations of circulating TPO in response to low platelet levels. Because we could not detect any difference in TPO mRNA levels between c-mpl-'-and wild-type animals in the livers, kidneys, or any other organ, we studied the ability of the platelets themselves to regulate the TPO levels. In contrast to platelets from the c-mp1"-mice, platelets from normal mice are capable of binding, internalizing, and degrading TPO. The absence of receptors for TPO in the c-mpl-" mice leads to a slower rate of clearance from the plasma and a longer initial halflife of TPO. Finally, reconstitution of normal platelets in c-mpl-" mice, by injection of purified normal platelets, rapidly decreases the plasma levels of TPO to those found in normal mice. Together, these data strongly suggest that circulating TPO levels are regulated by the most mature cells of the megakaryocyte lineage.
mates (c-m~I+/+),'~ were maintained in specific pathogens free (SPF) conditions. The average weights (mean 2 SD) were 28.3 2 3.7 and 30.0 t 4.2 g for the c-mpl"-and c-mpl+'+ mice, respectively. Some in vitro studies were performed using CD-l (normal) mice. All studies were approved by the Genentech Animal Use and Care Committee.
S I nuclease protection assay. TPO mRNA was detected using an S1 nuclease protection assay using a 32P 5' end-labeled 60-mer oligonucleotide (5'GGGGTCCTTCTGAGCTGTGGTCCTGCCCT-GTAGAGGAAGCTGGGAATACAGTTAGATCTA3') having at the 5' end 44 nucleotides antisense to amino acids 110-124 of murine TPO (mature form) followed by 16 nucleotides of irrelevant sequence. The S1 nuclease assay was performed essentially as previously described.24
Tissue distribution of '251-recombinant human TPO ('251-rhTPO). rhTPO was iodinated by the Indirect Iodogen method,25 purified by size-exclusion chromatography (SEC), and formulated in 10 mmoll L Tris, 0.15 m o m NaC1, 0.01% Tween 20, pH 7.4 (TNT). The specific activity of the radiolabeled material was 65 pCilpg protein.
To prevent accumulation of '''I in the thyroid of the animals, mice were injected subcutaneously with 0.1 mL of a 50 mg/mL solution of sodium iodine 48, 24, and 1 hour before administration of the tracer. Mice (n = 3) were injected intravenously (IV) with 0. Whole citrate blood (0.1 mL) or plasma (0.05 mL) was counted to obtain the total cpm per sample. The samples were then diluted to 0.5 mL in PBS containing 1.0% bovine serum albumin and vortexed and 0.5 mL of 20% TCA was added to each sample, vortexed, and incubated at 4°C for 15 minutes. The samples were then centrifuged at 2,950g for 10 minutes, the liquid phase was aspirated, and the remaining pellets were analyzed to obtain the TCA-precipitable counts per sample. The data were then expressed as cpm per gram for blood and cpm per milliliter for plasma samples. To determine blood cell-associated radioactivity, whole citrate blood (0.1 mL) was counted to obtain the total cpm per sample. The samples were diluted to 1 mL in PBS, vortexed, and then centrifuged at 2,950g for 10 minutes; the liquid phase was aspirated and the remaining blood cell radioactivity was counted. The data were then expressed as the percentage of radioactivity associated with the cell pellet for the 0.1 mL whole blood sample.
In vitro binding of '"I-rmTP0 by platelets. Citrated blood was collected via tail bleeds from 6 c-mpl-" and 6 c-mpl+'+ mice. Platelet-rich plasma (PRP) was prepared by centrifuging whole citrate blood in an Eppendorf microfuge for 3 seconds at full speed (14,000 rpm). The blood samples were then allowed to settle for 5 minutes before the PRP was harvested from the layer above the blood cell pellet. The above process was then repeated to collect residual PRP. The PRP (0.18 mL) was incubated with approximately 67,000 cpm of '251-recombinant mouse TPO ('251-rmTPO) + 10 pg cold rmTPO (nonspecific binding [NSB]) or TNT buffer (total binding [TB]) for 1 hour at 37°C. After 1 hour, 0.75 mL of ice-cold TNT buffer was added to the tubes. Samples were then centrifuged at 14,000 rpm in an Eppendorf microcentrifuge for 15 minutes, the supernatant was removed, and the pellet was counted for 1 minute. Total radioactivity and the percentage of bound (cpm in pellet/total cpm added) were calculated for each group of samples. The experiment was performed twice in triplicate.
To measure the amount of 'ZSI-rmTPO bound by the PRP that was internalized, mouse PRP was prepared from CD-l mice as above. A total of 0.8 mL of PRP was incubated with approximately 17.000 cpm of '"I-rmTPO + 10 pg cold rmTPO (NSB) or TNT buffer (TB) for 1 hour at 37°C or 4°C. After l hour, 10 pg of cold rmTP0 was added to some samples to displace any 1Z51-rmTP0 bound to the surface of the platelets. The samples were then incubated for an additional 10 minutes before the addition of 0.75 mL of ice-cold TNT. Samples were then processed as above.
Binding and degradation of 'z51-rmTP0 by platelets. Approximately 35,000 cpm of '%TIITPO was added to 0.18 mL of mPRP with or without increasing concentrations of cold rmTP0. Samples were incubated for 30 minutes at 37°C and then 0.75 mL of icecold TNT was added to the tubes and the samples were processed as described above. The amount of radioactivity in the platelets was used to determine receptor affinity using a 4-parameter curve fit (KaleidaGraph; Synergy Software, Reading, PA), and the number of binding sites per platelet was calculated by Scatchard analysis.
To test the ability of platelets to degrade TPO, approximately 30,000 cpm of '251-rmTP0 was added to 0.18 mL of mPRP with or without 10 pg nonlabeled rmTPO (NSB). Samples were incubated for 2 hours at 37°C and 0.75 mL of ice-cold TNT was added to wash the samples before centrifugation. A total of 0.15 mL of sodium dodecyl sulfate (SDS)-sample buffer (containing 5 mmoUL DTT) was added to the platelet pellets, and pellets were boiled at 100°C for 5 minutes. Samples of solubilized platelets were then electrophoresed on 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The gels were dried and exposed to X-Omat film (Eastman Kodak, Rochester, NY) for 3 to 5 days.
Pharmacokinetics of '251-rmTP0 in c-mpl-/-mice. Female cmpl-" and c-mpl"+ mice received approximately 3.24 pCi of I2'IrmTP0 as an IV bolus via a lateral tail vein. Mice (n = 2) were then killed at selected times postinjection and plasma-associated radioactivity was determined as above.
Pharmacokinetic parameters were estimated by fitting TCA-precipitable plasma cpm per milliliter versus time data to compartmental models using nonlinear least-squares regression analysis (PCNON-LIN, v 4.0; Statistical Consultants, Lexington, KY).
Preparation of washed murine platelets. Normal mouse (1 29) PRF' was prepared as mentioned earlier. Prostaglandin Iz (PG12) was added to a final concentration of 300 ng/mL and, after 10 minutes, apyrase was added at a final concentration of 5 U/mL. After another 10 minutes, the PRP was centrifuged at 1,600g for 5 minutes. The platelets were resuspended in 5 mL of Tyrode's buffer (0.14 mol/ L NaCI, 0.0027 m o m KCI, 0.012 m o m NaHC03, 0.0004 m o m NaZHPO,, pH 7.4, with 5.5 mmom glucose, 10 mmom HEPES, and 2% bovine serum albumin [BSA], ie, Tyrode's-BSA) containing 300 nglmL PGIz and 1 U/mL apyrase. After centrifugation, the platelets were resuspended in 5 mL Tyrode's-BSA with 0.2 UlmL apyrase, centrifuged, and then resuspended in Tyrode's buffer without BSA. Platelets were counted on a Baker System 9000 Diff Model cell counter (Serono Baker, Allentown, PA). To allow recovery from the PGI, treatment, the washed platelets were allowed to stand in the dark for a minimum of 2 hours at room temperature before use.
Data analysis. All tissue, blood, and plasma data were tabulated and presented as mean 2 SD, unless otherwise noted. Statistical analysis was performed on data expressed as cpm per gram of tissue weight except for the blood cell-associated data. Selected data were compared by ANOVA and values of P S .05 were considered for further analysis by Tukey's test.
RESULTS
TPO mRNA levels in c-mpl-" mice. Northern blot analysis of TPO mRNA levels in tissues from normal humans or Analysis of TPO mRNA expression by S1 nuclease protection assay. The S1 nuclease protection assay was conducted using a 60-base oligonucleotide (described in the Materials and Methods) designed to generate a TPO-specific protected fragment of 44 bases. RNA was isolated from the liver and kidney of wild-type, heterozygote, and c-mpl-deficient mice, as indicated. The absence of a protected band in the presence of nonspecific RNA (RNA) is shown as is the undigested probe (probe). Molecular weight markers (pBR322 Mspl digest) are included for comparison. mice indicates that the basal level of expression was highest in the liver and the kidney. To determine if mRNA expression was increased in a thrombocytopenic situation, in which high levels of circulating TPO could be detected, we have used an SI nuclease protection assay to compare the levels of TPO mRNA between wild-type and c-mp1-l-mice. Using 10 pg of total liver RNA or S0 yg of total kidney RNA, a 44-bp fragment was protected. However, no difference in intensity of the bands between the various mice could be detected (Fig l ) . Also. there was no detectable signal in lung, muscle, brain, spleen. thymus. or heart (data not shown). These data suggest that there is no transcriptional regulation of the TPO gene in response to thrombocytopenia. TPO tissue distribution of '".'I-rhTPO in mice. To determine if binding by the c-mpl receptor on platelets could be the mechanism by which circulating levels of free TPO are regulated. we measured the in vivo distribution of a dose of radiolabeled TPO in c-mpl"' and c-mp1-I-mice (Table l) .
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Radioactivity was found mainly in the highly perfused tissues at all time points in both groups of mice. However. the blood and the spleen of the c-mpl"' mice contained the most radioactivity and only the spleen achieved a tissue-toblood ratio greater than I . The spleen to blood ratios in the c-mpl"' mice were 0.37, 1.08, and 1.30 at S minutes. 3 hours, and 24 hours postdose. respectively. In contrast. no specific uptake of radioactivity was observed in any organ of the c-mpl-" mice at any of the time points measured.
The amount of radioactivity in the spleen of c-mpl"' mice was significantly greater than that in the c-mp1-l-mice at all time points (Fig 2A) . The amount of "I-rhTPO associated with blood cells also differed between the two groups of mice (Fig 2B) . However, no increase in blood cell-associated radioactivity was found over time in the c -m p l~/ -mice. There also appeared to be a difference in the amount of radioactivity in the lungs at 3 and 24 hours ( Table I ) . but these differences were not statistically significant. The accumulation of TPO in the blood cells and spleen suggests that TPO is bound to the platelets and that this process is c-mpl dependent.
Rindiq of TPO fo murine PRP. To demonstrate that platelets bind TPO through c-mpl, we compared the in vitro binding of '"I-rmTP0 by mouse PRP prepared from c-mpl'" or c-mpl-" mice (Fig 3A) . The PRP from the c-mpl'" contained 4.7-fold more platelets than did the PRP from the cmpl-/-mice. No specific binding of ' % m T P O to PRP from c-mpl-/-mice could be detected. Total binding to the PRP from c-mpl"' mice was approximately 100-fold higher than to PRP prepared from c-mpl-/-mice, with 96% of the counts being specifically bound.
When PRP from normal mice were incubated at 4°C to slow down internalization of ligand, 85% less '"I-rmTPO was found associated with the pelict compared with the level at 37°C (Fig 3R) . To determine what fraction of the bound TPO was present inside the cell at equilibrium. 10 p,g of cold rmTPO was added to the PRP to displace surface-bound "'I-rmTPO after the 1 hour of incubation at 37°C. A 34% decrease in the amount of radioactivity was observed, indicating that two-thirds of the radioactivity associated with the PRP pellet was nondisplaceable or internalized. To further analyze the number and affinity of TPO receptor sites present on normal platelets, binding of '"1-rmTPO to normal PRP prepared from CD-l mice was determined in the presence of increasing concentrations of unlabeled m T P 0 (Fig 4) . Affinity data from the 4-parameter fit indicated an approximate receptor affinity of 560 pmoIL, and data from Scatchard analysis suggests approximately 220 binding sites per platelet. To test the ability of PRP to degrade TPO, mPRF' was incubated in the presence of 30,000 cpm of I2'I-rmTPO with or without 10 pg nonlabeled rmTP0 for 2 hours at 37°C. Platelets were then washed with icecold excipient and analyzed by SDS-PAGE on a 10% gel. As can be seen in Fig 5, ' 251-rmTP0 bound to platelets from CD-l mice was partially degraded into fragments of less than 50 k D . In similar experiments, very little degradation of I2'I-rmTPO was observed when incubated at 37°C in the presence of buffer only or platelet-poor plasma (data not shown). The ability of the platelets to bind and degrade I2'IrmTPO was greatly diminished by the addition of excess nonlabeled rmTP0 to the incubation, suggesting a saturable process.
Pharmacokinetics studies.
If the plasma clearance of TPO is mediated by specific binding to c-mpl on platelets, one would predict that the clearance of TPO from the plasma in the c-mpl-/-mice would be dramatically affected. The IV bolus pharmacokinetic profiles of 12sI-rmTFQ in c-mplc/+ and c-mpl-/-mice were therefore determined (Fig 6) . The initial volume of distribution was 40% larger and the steadystate volume of distribution was nearly sixfold larger in the c-mpl+/+ mice compared with that in the c-mp1"-mice, suggesting distribution of '"I-rmTPO out of the plasma and into platelets or other tissue sites. Because of the specific removal of TPO from the plasma by the platelets, the initial half-life (tlI2 initial) was shorter and the overall systemic clearance of 1251-rmTP0 (CL/W) was much faster in the cmpl+'+ mice than in the c-mpl-/-mice. removal of '2SI-rmTP0 in the c-mpl+'+ mice was also evidenced by a much greater percentage of blood cell-and spleen-associated radioactivity at each time point (data not shown).
Injection of normal platelets into c-mpl-/-mice. To de-
termine if normal platelets themselves were capable of regulating the level of circulating TPO in c-mpl-" mice, washed platelets were prepared from normal 129 mice and injected into c-mpl-" mice. Two hours after the injection, platelet counts were determined and the TPO levels were measured by the BalF3-mpl proliferation assay'' (Fig 7) . Platelet counts of the c-mpl-" mice injected with platelets increased dramatically to approximately 1.2 million/pL, whereas platelet counts of mice injected with buffer alone did not change. Serum from the control c-mpl-'. mice induced maximal stimulation of Ba/F3-mpl cell proliferation at 1/20 dilution, whereas no stimulatory activity could be detected in the serum of c-mpl"-mice injected with normal platelets, suggesting that platelets alone reduced serum TPO to normal (undetectable) level. Five days after the platelet injection, platelet counts returned to preinjection levels and serum TPO levels were again increased.
DISCUSSION
The physiologic responses to thrombocytopenia have been well characterized. These studies have led to the identification of a factor present in the circulation of thrombocytopenic animals that was capable of stimulating megakaryocytopoiesis and ultimately led to the cloning of TP0.3-5 Elevated levels of TPO present in the circulation of acutely thrombocytopenic animals results in an increase in the number and ploidy of megakaryocytes in the bone marr~w.~',~' However, the mechanisms responsible for increasing the circulating levels of TPO remain to be elucidated. By analogy with the EPO system, one can hypothesize a platelet-sensing mechanism that, in response to the detection of a reduced platelet mass, first stimulates the transcription of the TPO gene and then increases the synthesis and release of TPO into the blood stream. However. using S I nuclease protection assay, we were unable to detect any differences in TPO mRNA levels in any tissue between the c-mpl-" and c-mpl"' mice. c-mpl-/-have low levels of platelets and megakaryocytes and high circulating levels of TP0.l5 Similar results were observed in models of transient thrombocytopenia induced by radiation in which increased levels of TPO could also be detected in the circulation (data not shown). These results suggest that transcriptional regulation of the TPO gene is not involved in the increased levels of TPO observed in response to thrombocytopenia. These data also correlate with the phenotype of TPO-" mice, in which heterozygous mice have a platelet level intermediate between the wild-type and the TPO-/-mice, again suggesting that TPO production is not increased in response to changing platelet level^.'^ In an alternative model originally suggested by de Gabriele and Penington," TPO could be released into the circulation at a constant rate and the level of circulating TPO could be regulated by the platelets themselves. This model was also proposed by Kuter et al,'x."' who have recently shown in rabbits that plasma TPO levels increased after Busulfan-induced thrombocytopenia and that infusion of platelets into these rabbits decreased the plasma levels of TPO. To further investigate the mechanism of regulation of TPO levels, we have analyzed the capacity of normal and cmpl-" platelets to bind and internalize TPO. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From platelets bind TPO with a high affinity, whereas there was no detectable TPO binding to platelets from c-mpl-l-mice. Normal platelets in mice have approximately 220 binding sites per platelet. Because the circulating level of platelets in mice approximates 10" platelets& these data would suggest that a mouse has a binding capacity for TPO of approximately 350 pmoyL, which is very similar to the affinity constant derived from our binding studies. However, this number is likely to be an underestimate, because under normal physiologic conditions, binding sites on circulating platelets will likely be partially saturated with endogenously produced TPO. These data suggest that the circulating platelets have the capacity to bind physiologically relevant concentrations of TPO. Furthermore, normal platelets can also internalize and degrade TPO, therefore improving the efficiency by which "PO is removed from the circulation.
The in vivo tissue distribution data indicate that the major tissues of accumulation are the spleen and blood cells in cmpl+/+ mice. Although radioactivity was found in most highly perfused tissues, only the spleen had a tissue to blood ratio of greater than one suggesting net tissue uptake. However, binding to both tissues is likely due to the presence of platelets. The spleen does contain some megakaryocytes that could also bind TPO, but a large portion of the pool of platelets in a mouse is present in the spleen. These data are consistent with the ability of mouse platelets to bind, internalize, and degrade radiolabeled TPO in vitro. In TPO-/-mice that have normal c-mpl but low platelet numbers, little in vivo uptake of radiolabeled TPO was present in either the blood cells or spleen, suggesting that binding to these tissues is at least partially dependent on platelet numbers (data not shown).
The role that c-mpl and platelets play in the regulation of circulating TPO levels was most dramatically shown in the pharmacokinetic study. There was a substantial decrease in the volume of distribution at steady state and clearance of TPO in the c-mp1-l-when compared with the c-mpl+/+ mice. The increased volume of distribution and faster clearance in the c-mpl+/+ mice is likely due to the binding and removal of 1251-rmTP0 by platelets via the c-mpl receptor. This was reflected by a difference in the amount of radioactivity associated with the blood cells and spleen over time in the cmpl+/+ mice compared with the c-mpl-/-mice. The amount of TPO present in an unbound form in plasma over time is much greater in the mice that lack the c-mpl receptor. These data also indicate that initial platelet numbers will likely play a major role in the overall exposure of an animal or patient to exogenously administered TPO. Cell-mediated regulation of plasma levels has been suggested for other hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF) and colony-stimulating factor-l (CSF-I). Bartocci et a12' investigated the tissue uptake and clearance of circulating TPO levels were determined 2 hours and 5 days after injection. TPO levels were measured using the Ba/F3-mpl proliferation assay.
radiolabeled CSF-1 in mice. Most radiolabeled CSF-l was found in the liver bound to Kupffer cells, and binding of radiolabeled CSF-1 to these cells was saturable at low protein concentrations. When Bartocci et aIz8 depleted macrophages by injection of y-carrageenan, an apparent decrease in clearance was observed. In early clinical trials with G-CSF, a reciprocal relationship between free G-CSF and neutrophil levels was ~bserved.'~ To show that endogenous levels of TPO were directly regulated by platelets, normal platelets were reinjected in cmpl-" mice and their TPO levels were monitored. As soon as 2 hours after their platelet levels were restored to normal, the plasma TPO levels of the c-mpl-'-mice were undetectable. These results indicate that, in vivo, platelets can directly regulate TPO levels. However, it remains possible that, in a situation in which platelet levels are low but megakaryocyte numbers are normal or increased, circulating levels of TPO FIELDER ET AL could remain low because it would be bound to the megakaryocytes themselves. This may help explain why NF-E2 knock out mice, which have no detectable platelets but increased megakaryocyte numbers, do not appear to have increased TPO levels." This could also explain why most patients diagnosed with immune thrombocytopenic purpura (ITP) do not have abnormal TPO levels. However, our data suggest that functional platelets play a significant role in regulating circulating TPO levels.
We provide here a detailed analysis of the mechanism by which platelets control circulating levels of TPO and thereby regulate megakaryocytopoiesis to achieve platelet homeostasis. We suggest that TPO is constitutively synthesized and released into the circulation by the liver and/or the kidney. In situations in which platelet levels are normal, our in vivo and in vitro data show that platelets remove most of the TPO from plasma via binding to the c-mpl receptor, where it is then internalized and degraded. The presence or absence of c-mpl on platelets dramatically affects the clearance of an exogenously administered dose of TPO. Under conditions of severely decreased platelet and megakaryocyte numbers, such as those encountered in patients undergoing chemotherapy or radiation therapy, the observed increase in TPO plasma levels is likely due to the absence of this clearance mechanism and is not a consequence of increased production. This model provides a simple mechanism for end-cell regulation of TPO that enables rapid reaction in response to changes in platelet mass.
